An interventional study of Patient component and Organisational component in Aortic Valve Stenosis, sponsored by University Hospital, Rouen. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by University Hospital, Rouen · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Aortic Valve Stenosis with a site in France — 22 open to participants now, 34 under way, 2 of them phase 3. Aortic Valve Stenosis · France.
Among the 131 studies in Aortic Valve Stenosis with a site in France, this one is the 15th largest by enrollment of the 69 interventional ones that give a count, is one of 4 that started in 2022, is one of 58 with no phase, and was the 108th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →22 of the 131 studies in Aortic Valve Stenosis with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Ceric Sàrl · Sites in France, Austria, Estonia and 11 more countries
Ages 65–75
Hospices Civils de Lyon · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+
Novartis Pharmaceuticals · Sites in France, United States, Argentina and 20 more countries
Ages 6–11
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8 · Phase 4 1
First in 2002; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 828 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 186 across the 69 interventional studies, 470 across the 62 observational. Of the 79 that completed or were terminated, 13 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 131 have an industry lead sponsor. The 10 most frequent:
University Hospital, Rouen is the lead sponsor of 418 studies on the registry; 106 are open to participants now.
University Hospital, Rouen has 7 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Aortic Valve Stenosis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06215378Phase 3Assistance Publique - Hôpitaux de ParisAntagonization of Heparin With Protamine Sulfate After TAVI | 2027-03-01 |
| NCT03728049University Hospital, LilleVon Willebrand Factor Point-of-care Testing to Improve Minimally Invasive TAVI Outcomes | 2026-12 |
| NCT02972008University Hospital, LilleIdentification of Epigenetic Risk Factors for Ischemic Complication During the TAVR Procedure in the Elderly | 2027-02 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT07520591Cardiawave SAValvosoft Outcomes Registry for Real-World Evidence | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 131 studies in Aortic Valve Stenosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population. Although significant progress has been made in understanding the pathophysiological mechanisms underlying the onset and progression of AS, there is no medical treatment to slow or prevent its progression. The only treatment available is Aortic Valve Replacement (AVR) performed by surgery or by catheterization (TAVI).
Once a diagnosis has been made and the decision to treat these patients has been taken, the procedure (AVR or TAVI) must be performed rapidly given the poor prognosis of the disease without treatment. Studies have shown that on the waiting list, the probability of death and hospitalisation for heart failure increases with time. This delay could also reduce the effectiveness of TAVI, thus affecting the performance of the healthcare system.
In this study, an intervention combining an e-health component (tool intended for patients, families and health professionals in contact with patients), and an organisational component (for TAVI implanting centres) has been designed. The aim of this study is to evaluate the effectiveness of this intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The randomized centres in this group will not change their practices.
The randomized centres in this group will be required to present patients with: * A short introductory video, viewed on a tablet during hospitalization for coronary angiography, * A paper booklet, * A website.
Other: Patient component
The randomized centres in this group will be provided with a list of organisational changes to be implemented to improve patient care times.
Other: Organisational component
The randomized centres in this group will have to implement the two components.
Other: Patient component · Other: Organisational component
Video, booklet, website
Coronarography, CT-scan, anesthesia...
To evaluate the effectiveness of an intervention combining a patient component and an organisational component
Percentage of patients with a TAVI indication with a time to TAVI procedure of less than 2 months
Time frame: Month 6
Time to care, in days
The time to care is the number of days between the date of the initial consultation during which a TAVI is proposed and the date of the TAVI procedure
Time frame: Month 6
Mortality rate
The mortality rate will be measured between the initial consultation during which a TAVI is proposed and the TAVI procedure, and in the three months following the procedure
Time frame: Months 3 and 6
Patients' health-related quality of life
Patients' health-related quality of life will be measured using the 5-level EQ-5D version (EQ-5D-5L).
Time frame: Baseline, Months 3 and 6
Patient knowledge of the disease and the TAVI procedure
Patients' knowledge of the disease and the TAVI procedure will be measured by their score to an ad hoc questionnaire (0: minimum score - 26: maximum score).
Time frame: Baseline, Month 3
Medication compliance
Patient medication compliance will be measured using a questionnaire developed by Girerd et al, with a score going from 0 (lowest compliance) to 6 (maximum compliance).
Time frame: Month 6
Patient satisfaction
Patient satisfaction with the care they received and (for the group receiving the patient component) with the patient component of the intervention will be measured using a 0 to 10 Likert scale
Time frame: Month 6
Number of visits to the patient section of the website
The number of visits to the website will be assessed through Googleanalytics®
Time frame: Month 6
Number of visits to the professional section of the website
The number of visits to the website will be assessed through Googleanalytics®
Time frame: Month 6
Acceptability of the intervention for participating centers
The acceptability of the intervention will be assessed through an ad hoc questionnaire addressed to TAVI centers and peripheral hospitals performing the coronary angiography of the pre-TAVI assessment.
Time frame: Month 6
Intervention components' dose and fidelity
Number of different activities really performed for each component of the intervention / number of activities planned for each component according to the protocol.
Time frame: Month 6
Reached populations
Percentage of target individuals who benefit from activities of each component of the intervention
Time frame: Month 6
Intervention components' adaptation
Number of activities performed which have been modified to adapt them to the local context / total number of activities performed. A description of the adaptations performed will be provided.
Time frame: Month 6
Incremental cost-effectiveness ratio
The incremental cost-effectiveness ratio will be expressed in cost per quality-adjusted life-year (QALY) gained, derived from the EQ-5D-5L questionnaire
Time frame: Month 6
Ran from Oct 2022 to primary completion in Oct 2025, 35 months.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's 35 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2024 → Oct 2025, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.